MSTN and sarcopenia: Accordingly, myostatin inhibitors, including antibody, recombinant protein, and peptide, have been shown to be useful tools for inducing muscle growth, leading to the promising treatment of muscle atrophic disorders, such as muscular dystrophy, sarcopenia, and cancer-associated cachexia [9,10,11,12,13,14,15,16,17,18,19,20].